Vol 5, No 1 (February 01, 2016): Translational Cancer Research

Emerging roles of FGF signaling in hepatocellular carcinoma

HER2 as a therapeutic target in gallbladder cancer—aye or nay?

Expanding landscape of CDKN1A (p21) functions: CDKN1A-mediated radioresistance of dermal Langerhans cells and its impact on the immune system

Activated status of Hedgehog pathway in oral squamous cell carcinoma (OSCC): the door is still open

Postoperative treatment for head and neck cancer: the emerging role of EGFR-targeted therapy

Use of yttrium-90 radioembolization for patients with unresectable liver metastases: experience from a single center

Clinical outcomes of patients treated with accelerated partial breast irradiation with high-dose rate brachytherapy: Scripps Clinic experience

Hyponatremia in small cell lung cancer is associated with a poorer prognosis

Extracellular matrix in gene expression profiling of cancer

Protein kinase CK2 in DNA damage and repair

Natural (tryptophan) metabolites—mediated activation of aryl hydrocarbon receptor inhibits cancer stem cell signaling: what does it mean to prevent cancer recurrence?

“Boom-Boom” radioimmunotherapy of lymphomas: are two magic bullets better than one?

Identification of the hidden survival advantage for anti-angiogenic therapy in glioblastoma

Irradiation and combination immunotherapy

A circadian prelude to regulation of angiogenesis and thrombosis by prolactin and plasminogen activator inhibitor-1

Radioimmunotherapy in limited-stage diffuse large B-cell lymphoma

Role of season in overall survival of patients with bone metastasis undergoing radiotherapy